Healthcare · Profile from Healthcare Research Companion
Mark Cuban Cost Plus Drug Company, PBC
A Dallas online pharmacy and generic-drug supplier, set up as a public benefit corporation, that publishes the same formula for every price: what it paid for the drug, plus a 15% markup, plus a flat pharmacy fee, plus shipping. Co-founded by radiologist Alex Oshmyansky and funded by billionaire investor Mark Cuban, it launched in January 2022 with about 100 generics. It became the best-known challenger to the opaque pricing of the pharmacy benefit managers (PBMs). Its significance is less its size, which is small next to CVS, Express Scripts or Optum Rx, than the price benchmark it put in public view. Employers, transparent PBMs, health plans, independent pharmacies and, from 2025, the federal government's TrumpRx site now refer to it.
At a glance
- Founded
- 2018, Dallas, Texas, as Osh's Affordable Pharmaceuticals (Alex Oshmyansky); renamed and relaunched with Mark Cuban as Mark Cuban Cost Plus Drug Company; online pharmacy opened January 2022
- Founders
- Dr. Alex Oshmyansky (radiologist, CEO) and Mark Cuban (investor, co-founder and public face)
- Headquarters
- Dallas, Texas
- Ownership / structure
- Private public benefit corporation (PBC); funded by Mark Cuban; no outside venture rounds disclosed
- Leadership (2026)
- Alex Oshmyansky, CEO; Mark Cuban, co-founder (verify other executive titles)
- Segment
- Pharmacy and PBM ecosystem: mail-order pharmacy, generic sourcing and wholesale, drug manufacturing, network partner to PBMs and plans
- Payer and patient
- Cash-paying patients (insured or not); employers and plans through transparent PBMs; independent pharmacies and health systems buying at cost-plus prices; patients receive mostly generic maintenance drugs
- Scale
- ~100 drugs at launch (January 2022); catalogue grew to roughly 2,000–2,500 products by 2025 (reported, verify); millions of customers claimed by Cuban (verify); revenue not disclosed
- Capital raised / valuation
- Self-funded by Cuban; investment in the pharmacy, warehouse and Dallas manufacturing plant not disclosed
- Signature moves (incl. failures)
- 2022 launch and published cost-plus formula; PBC structure and self-funding; integrations with transparent PBMs and employers (2022 onward); Dallas manufacturing plant; Blue Shield of California unbundling (2023); independent-pharmacy and marketplace channels (2023 onward); TrumpRx partnership (2025–26, verify)
7 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2022
Dallas Manufacturing Plant
Vertical integration (manufacturing build-out)
2022
Launch and Cost Plus Pricing Model
Founding / launch / pricing change
2022
PBM and Employer Integrations
Partnership / distribution
2022
Public Benefit Corporation and Self Funding
Restructuring / capital strategy (legal form and funding choice)
2023
Blue Shield of California Unbundling
Partnership (payer contract)
2023
Independent Pharmacies and Marketplace
Partnership / distribution (new channels)
2025
TrumpRx Partnership
Partnership (government)